Related Experiment Video
Updated: Feb 27, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
[Effect on cryoablation of high-risk and locally recurrent prostate cancer: a Meta-analysis]
1Department of Ultrasound, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Abstract:
Objective: To discuss the curative effect and prognosis of cryoablation to high-risk and locally recurrent prostate cancer patients. Methods: Cryoablation related publications and relevant references were searched for potential pertinent articles until March, 2016.Articles were selected according to the exclusion criteria, Stata ver.11 was used to perform the statistical analysis. Results: 5-year biochemical disease-free survival of salvage ablation for prostate cancer was 45%(95% CI 0.43-0.47), in salvage radiotherapy of 45% (95% CI 0.44-0.47). The 5-year biochemical disease-free survival of high-risk prostate cancer cryoablation was 66%(95% CI 0.64-0.67). The result of high-risk prostate cancer radiotherapy and EBRT were respectively 61%(95% CI 0.60-0.63) and 54% (95% CI 0.52-0.56). Conclusions: The five-year biochemical recurrence of salvage cryoablation is similar to salvage radiotherapy. For high-risk prostate cancer, cryoablation shows an advantage than traditional EBRT radiation.
